Clinical Trial Update: VX-770 Expanded Access Program

View source ↗

Summary

Ivacaftor (VX-770) has received marketing approval for cystic fibrosis, as noted in Vertex's expanded access program update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• VX-770 (ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Status: APPROVED_FOR_MARKETING